Evidence map›Paper›PMID 41282777›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Recurrent

Jimmy Kizza, Thomas Katairo, Abel Kakuru, Bienvenu Nsengimaana, Trevor Esilu, Innocent Wiringilimaana, Francis D Semakuba, Inna Gerlovina, Nicholas Hathaway, Jessica Briggs and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Jimmy KizzaInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0003-0224-4044
Thomas KatairoInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0002-2002-8911
Abel KakuruInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0001-9941-1309
Bienvenu NsengimaanaInfectious Diseases Research Collaboration, Kampala, Uganda.
Trevor EsiluInfectious Diseases Research Collaboration, Kampala, Uganda.
Innocent WiringilimaanaInfectious Diseases Research Collaboration, Kampala, Uganda.
Francis D SemakubaInfectious Diseases Research Collaboration, Kampala, Uganda.
Inna GerlovinaUniversity of California, San Francisco, CA, USA.
Nicholas HathawayUniversity of California, San Francisco, CA, USA.ORCID 0000-0001-9639-2894
Jessica BriggsUniversity of California, San Francisco, CA, USA.
Stephen TukwasibweInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0002-6469-6516
Steven M KiwuwaMakerere University, Kampala, Uganda.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0001-9106-4234
Joaniter I NankabirwaInfectious Diseases Research Collaboration, Kampala, Uganda.ORCID 0000-0001-7818-3845
Grant DorseyUniversity of California, San Francisco, CA, USA.ORCID 0000-0003-0740-0317
Philip J RosenthalUniversity of California, San Francisco, CA, USA.ORCID 0000-0002-7953-7622

Funding

Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in UgandaU01AI141308 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DORSEY, MATTHEW G, ROSENTHAL, PHILIP JON · 2020 to 2024
$6.0M
Training in malaria surveillance, epidemiology and implementation science research to strengthen malaria policy and control in UgandaD43TW010526 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2017 to 2026
$2.3M
FIC NIH HHS D43 TW010526NIAID NIH HHS U01 AI141308
6 · The paper itself

Abstract

Background: Intermittent preventive treatment with monthly sulfadoxine-pyrimethamine (IPTp-SP) is recommended during pregnancy in malaria-endemic countries. However, widespread resistance of Methods: We sequenced 1377 samples collected from pregnant women enrolled in a trial comparing monthly SP, DP, and DP+SP for IPTp in Busia, Uganda and with asymptomatic parasitemia at the time of IPTp administration. We characterized known markers of drug resistance and assessed the 28-day cumulative risk of recurrent parasitemia, with genotyping to distinguish recrudescence from new infections. Results: Among 771 samples collected on the day IPTp was initiated, the prevalences of five resistance mutations in Conclusions: IPTp-SP had poor preventive efficacy and selected for increased drug resistance, questioning the value of this intervention.

Indexed as

dihydroartemisinin-piperaquineintermittent preventive treatmentMalariaPlasmodium falciparumpregnancyresistancesulfadoxine-pyrimethamineUganda

Identifiers

PMID41282777
PMCPMC12633580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.